Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target is $115.00.
Yanan Zhu has given his Buy rating due to a combination of factors including Sarepta Therapeutics’ progress in its LGMD clinical programs. The company is on track with its SRP-9003 program for LGMD2E/R4, expecting to report data from the Phase 3 EMERGENE study by mid-2025. This study, which completed patient enrollment and dosing in December 2024, includes both ambulatory and non-ambulatory patients, and its primary endpoint focuses on the expression of beta-sarcoglycan.
Additionally, the regulatory progress for SRP-9003 is promising, with a pre-BLA meeting confirming eligibility for the accelerated approval pathway. Sarepta plans to file a BLA in the second half of 2025, which is considered a positive catalyst. Furthermore, the company’s interactions with the FDA regarding the SRP-9005 program have been reassuring, indicating a clear path forward for its clinical trials. These developments collectively contribute to a derisked delivery and potential positive outcomes, supporting the Buy rating.
Zhu covers the Healthcare sector, focusing on stocks such as Sangamo Biosciences, Voyager Therapeutics, and Sarepta Therapeutics. According to TipRanks, Zhu has an average return of -13.2% and a 20.83% success rate on recommended stocks.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $203.00 price target.